Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001007965 | SCV001167693 | pathogenic | not provided | 2019-03-20 | criteria provided, single submitter | clinical testing | The C691X nonsense variant has been observed previously with other heterozygous USH2A variants in patients with USH2A-related disorders (Sandberg et al., 2008; Neuhaus et al., 2017). The variant is not observed in large population cohorts (Lek et al., 2016). This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. We interpret this variant as pathogenic. |
Labcorp Genetics |
RCV001007965 | SCV003524088 | pathogenic | not provided | 2022-05-29 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 816945). This premature translational stop signal has been observed in individual(s) with Usher syndrome (PMID: 15325563). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Cys691*) in the USH2A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in USH2A are known to be pathogenic (PMID: 10729113, 10909849, 20507924, 25649381). |
Genome- |
RCV003455064 | SCV004182464 | pathogenic | Usher syndrome type 2A | 2023-11-04 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005021315 | SCV005641090 | pathogenic | Usher syndrome type 2A; Retinitis pigmentosa 39 | 2024-06-17 | criteria provided, single submitter | clinical testing |